A nano-super material and its preparation method and application
Through the dual dynamic path control method, the self-assembly and self-emulsification of block copolymers are regulated, and complex gradual structure metamaterials at nanoscale are prepared, solving the problem of the limitations of existing metamaterials and the temperature limitations of the preparation methods. , achieving application and excellent performance in the field of biological imaging.
Patent Information
- Application Number
- CN202211245560.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-12
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-10-12
AI Technical Summary
Most of the existing metamaterials are micron, millimeter or even centimeter scales, which are difficult to apply in the field of medicine and biology, especially nanoscale. The preparation method mainly relies on thermodynamic methods, is limited by temperature, and lacks kinetic methods that are not limited by temperature.
Using a dual dynamic path control method, a nanoscale complex rank-structure metamaterial was prepared through non-solvent-induced self-assembly of block copolymer and osmotic pressure-induced internal self-emulsification process to regulate a constant temperature. The specific method includes mixing a block copolymer that can be coordinated with a metal ion with a solvent, adding alkali to prepare a dispersed phase solution, preparing a continuous phase solution with a surfactant and a high polar liquid, preparing an emulsion droplet once, and passing through a filter membrane Secondary emulsion droplets were prepared and cured to obtain nanometamaterial.
The nanoscale metamaterial with complex rank structure was successfully prepared, which achieved application in the fields of bioimaging and other fields. By regulating parameters such as Fe3+ concentration, the size range and structure of the metamaterial were controlled to obtain excellent bioimaging performance.
Smart Images

Figure HDA0003886411330000011 
Figure HDA0003886411330000012 
Figure HDA0003886411330000013
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of metamaterials, and in particular to a nano-metamaterial and a preparation method and application thereof. Background Art
[0002] Metamaterials are composite materials with complex artificial hierarchical structures, which include artificially designed (often periodic) structural units. By rationally regulating the key parameters of the structural units, composite materials can obtain physical and chemical properties that exceed those of conventional (or traditional) materials, such as a wide range of thermal expansion coefficients, programmable stiffness or dissipation, stimulus-triggered negative constitutive parameters, etc., and thus be widely used in acoustics, thermal, electromagnetics and other fields. Metamaterials have great potential both in basic research and practical applications, and are a unique and fascinating research field.
[0003] At present, the application fields, structural characteristics and preparation methods of metamaterials mainly have the following characteristics: First, the application fields of metamaterials are concentrated in the fields of acoustics, thermals, electromagnetism, etc. With the help of artificially designed structural units with sizes ranging from micrometers, millimeters or even centimeters, by modulating their interactions with factors such as electromagnetic waves, novel physical and chemical properties that have never existed in nature or chemically synthesized materials are produced. On this basis, new sub-fields of metamaterial research have gradually emerged, such as thermals and acoustics. Thirdly, for the preparation of metamaterials with complex hierarchical structures, most of the preparation methods are temperature-dependent thermodynamic methods. For example, using organic polymerization reactions, thermal deposition and other technologies, artificially designed structural units are prepared, and further assembled to obtain composite structures.
[0004] In summary, there are still some technical problems and technical gaps in the field of metamaterial technology: 1) Most of the current metamaterials are in the micron, millimeter or even centimeter scale. This scale range has size limitations in the application process in the medical and biological fields. For example, in the fields of cancer treatment, drug delivery, and biological imaging, materials are often required to be nanoscale. 2) Metamaterials with complex hierarchical structures are mostly prepared by thermodynamic methods, and kinetic methods that are not limited by temperature are rarely used. Thermodynamic methods rely on the temperature T of the system. eff (w), which limits the freedom in preparing metamaterials with complex hierarchical structures. Summary of the invention
[0005] The present invention provides a nano-metamaterial, a preparation method and an application thereof. The preparation method of the present invention adopts a dual dynamic path control method, which can simultaneously regulate two dynamic processes of the system to achieve stabilization of the non-equilibrium state in the system with constant temperature; the nano-metamaterial obtained by the present invention has a nano-scale structural unit and an overall size, and with the help of a complex internal hierarchical structure, it can be applied in the fields of biological imaging and the like.
[0006] The present invention first provides a method for preparing a nano-metamaterial, comprising the following steps:
[0007] (1) mixing a block copolymer capable of coordinating with metal ions, metal ions and a solvent, and then adding a base to prepare a dispersed phase solution;
[0008] (2) preparing a continuous phase solution with a surfactant and a highly polar liquid;
[0009] (3) preparing primary emulsion droplets using the dispersed phase solution and the continuous phase solution;
[0010] (4) The primary emulsion droplets are passed through a filtration membrane to prepare secondary emulsion droplets, which are then solidified to obtain the nano-metamaterial.
[0011] In the above-mentioned preparation method, the block copolymer is a block copolymer containing polyvinyl pyridine (PVP) segments;
[0012] Specifically, they may be polystyrene-b-poly 4-vinylpyridine (PS-b-P4VP), polystyrene-b-poly 2-vinylpyridine (PS-b-P2VP), polyethylene oxide-b-poly 2-vinylpyridine (PEO-b-P2VP), polydimethylsiloxane-b-polyvinylpyridine (PDMS-b-PVP), polymethyl methacrylate-b-polyvinylpyridine (PMMA-b-PVP), poly N-isopropylacrylamide-b-polyvinylpyridine (PNIPAM-b-PVP), polypropylene-b-polyvinylpyridine (PtBA-b-PVP), poly 2-vinylpyridine-b-poly 4-vinylpyridine (P2VP-b-P4VP), polyferric sulfate-b-poly At least one of poly(2-vinylpyridine) (PFS-b-P2VP), poly(acrylic acid)-b-polystyrene-poly-4-pyridine (PAA-b-PS-b-P4VP), poly(butylene)-b-poly(2-vinylpyridine)-b-poly(tert-butyl methacrylate) (PB-b-P2VP-b-PtBMA), poly(styrene)-b-poly(2-pyridine)-polystyrene (PS-b-P2VP-b-PS), poly(styrene)-b-poly(2-pyridine)-poly(ethylene oxide) (PS-b-P2VP-PEO) and poly(acrylic acid)-b-polystyrene-poly-4-pyridine (PAA-b-PS-P4VP); more specifically, polyethylene oxide-b-poly(2-vinylpyridine) (PEO-b-P2VP);
[0013] The metal ion is Pb 2+ , Fe 3+ , Mn 2+ , Gd 3+ , Pt 2+ , Pt 4+ and Pd 2+At least one of; specifically Fe 3+ ; the Fe 3+ FeCl 3 Join in the form of;
[0014] The solvent is CH 2 Cl 2 , N,N-dimethylformamide, toluene, chloroform, ethyl acetate and tetrahydrofuran; specifically, CH 2 Cl 2 and a mixed solvent of N,N-dimethylformamide; specifically, the CH 2 Cl 2 , the volume ratio of N,N-dimethylformamide is 10:1;
[0015] The alkali is sodium hydroxide and / or potassium hydroxide.
[0016] In the above preparation method, in the dispersed phase solution, the concentration of the block copolymer is 0.001-0.1 mg / mL, specifically 0.001 mg / mL; the concentration of the base is 3-5 μM, specifically 4 μM;
[0017] The molar ratio of the metal ion to the pyridine group in the block copolymer is 0 to 80:1; specifically, it can be 20 to 60:1; more specifically, it can be 40:1 or 60:1;
[0018] In the above-mentioned preparation method, in step (1), the method for preparing the dispersed phase solution is to dissolve the block copolymer that can coordinate with metal ions and the metal ions in the solvent, stir for at least 2 hours, then add the base and continue stirring until the system is in equilibrium to obtain the dispersed phase solution.
[0019] The base is added in solid form.
[0020] In the above preparation method, the surfactant is at least one of polyvinyl alcohol (PVA), sodium dodecyl sulfate, Span 80, dodecyltrimethylammonium bromide, sodium dodecylbenzene sulfonate and Tween 20;
[0021] The highly polar solvent is water, ethanol or methanol;
[0022] The mass percentage concentration of the surfactant in the continuous phase solution is 0.2-0.6%, and can be specifically 0.4%.
[0023] In the above-mentioned preparation method, in step (3), the method for preparing the primary emulsion droplets is microfluidics, ultrasound or mechanical stirring;
[0024] In step (4), the filter membrane used to prepare the secondary emulsion droplets is a filter membrane with a pore size of 0.10 to 0.45 μm; specifically, it can be a filter membrane with a pore size of 0.45 μm;
[0025] The curing is the natural volatilization of the solvent under room temperature.
[0026] Specifically, in the microfluidic method, the microfluidic device used is a microfluidic chip with a channel shape of T-type, L-type, Y-type or cross-type;
[0027] The material of the microfluidic chip is polydimethylsiloxane, quartz, glass or stainless steel;
[0028] The flow rate of the dispersed phase is 1-1000 μL min -1 , specifically 50 μL min -1 The flow rate of the continuous phase is 1 to 1000 mL min -1 , specifically 5-6 mL min -1 .
[0029] The present invention also provides a nano-super material prepared by the above preparation method.
[0030] Specifically, the nano-metamaterial may be Fe 3+ -OCPCs nano-metamaterial, which is a composite nanoparticle with a complex hierarchical structure; the Fe 3+ -OCPCs are composed of alternating PEO and Fe 3+ / P2VP is an onion ring-shaped multilayer shell and core, with Fe 3+ / P2VP is a spherical nanoparticle with a porous crown, with an overall size of 520-600nm, a core region size of 180-200nm, a shell region size of 8-15nm / layer, a crown region size of 0-100nm, and a pore size distribution within the crown of 0-60nm.
[0031] The application of the above-mentioned nano-metamaterials in magnetic resonance imaging or 7T ultra-high field magnetic imaging also falls within the protection scope of the present invention.
[0032] In the above application, in the magnetic resonance imaging or 7T ultra-high field magnetic imaging, the nano-metamaterial is used as a T 1 Contrast agent.
[0033] The technical route of the present invention adopts a two-stage emulsification technology: the first-stage emulsification adopts microfluidic technology to prepare micron-sized emulsion droplets; the second-stage emulsification adopts membrane emulsification technology to prepare micro-nano-sized emulsion droplets.
[0034] The dual kinetic pathway control preparation used in the method of the present invention mainly includes the regulation of the following two kinetic processes:
[0035] (1) Kinetics of non-solvent-induced block copolymer self-assembly;
[0036] (2) The dynamic process of self-emulsification inside droplets induced by osmotic pressure.
[0037] By regulating Fe 3+ Specific parameters such as concentration can simultaneously control the above two dynamic processes in the system, thereby precisely regulating the complex hierarchical structure of nano-metamaterials.
[0038] The present invention has the following advantages:
[0039] (1) Based on microfluidic technology, the present invention adopts a dual-kinetic path control preparation strategy. By regulating the two kinetic processes of block copolymer self-assembly and emulsification of emulsion droplets in monodispersed emulsion droplets, a nano-metamaterial with a core-onion ring-shaped multilayer shell-porous crown with an overall size of 560±36nm and a structural unit size of 5-10nm is prepared;
[0040] (2) Compared with the traditional thermodynamic method for preparing metamaterials, the method of the present invention does not depend on the system temperature T eff (w), by regulating Fe 3+ By adjusting key parameters such as concentration, the size range of metamaterials was successfully controlled to the nanoscale and excellent biological imaging performance was achieved. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 Fe 3+ 0.02 -SEM images of OCPCs, scale bar is 100 nm.
[0042] Figure 2 Fe 3+ 0.02 -TEM image of OCPCs, scale bar is 50 nm.
[0043] Figure 3 Fe 3+ 0.02 -Schematic diagram of the three-dimensional model of OCPCs.
[0044] Figure 4 Fe 3+ 0.04 -SEM images of OCPCs, scale bar is 100 nm.
[0045] Figure 5 Fe 3+ 0.04 -TEM image of OCPCs, scale bar is 50 nm.
[0046] Figure 6 Fe 3+ 0.04 -Schematic diagram of the three-dimensional model of OCPCs.
[0047] Figure 7 Fe 3+ 0.06 -SEM images of OCPCs, scale bar is 100 nm.
[0048] Figure 8 Fe 3+ 0.06 -TEM image of OCPCs, scale bar is 50 nm.
[0049] Fig. 9 Fe 3+ 0.06 -BET data chart of OCPCs.
[0050] Fig.10 Fe 3+ 0.06 - TEM pseudo-color image of OCPCs.
[0051] Fig.11 Fe 3+ 0.06 -Schematic diagram of the three-dimensional model of OCPCs.
[0052] Fig.12 Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 -P2VP T 1 Weighted MR imaging.
[0053] Fig.13 Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 -Relationship between the longitudinal relaxation rate of P2VP and contrast agent dosage.
[0054] Fig.14 Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 -Biological toxicity of P2VP.
[0055] Fig.15Fe was injected into the axilla of mice 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 -MR imaging after P2VP.
[0056] Fig.16 Injection of Fe into zebrafish embryos under high magnetic field 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 - MR imaging after P2VP; Fig.16 (a) is Fe 3+ 0.06 -P2VP, (b) Fe 3+ 0.02 -OCPCs; (c) Fe 3+ 0.06 -OCPCs. DETAILED DESCRIPTION
[0057] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, but not for limiting the scope of the present invention.
[0058] The experimental methods in the following examples are all conventional methods unless otherwise specified.
[0059] The quantitative tests in the following examples were all repeated three times, and the results were averaged.
[0060] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0061] The PEO-b-P2VP used in the following examples was purchased from Polymer Source, Inc. Canada; the number average molecular weight thereof was 13,000, and the mass percentage of PEO was 77%.
[0062] The number average molecular weight of P2VP (poly 2-vinylpyridine) used below is 4,800.
[0063] PVA (polyvinyl alcohol) is 1788 type polyvinyl alcohol.
[0064] The Fe 3+ 0.06 -P2VP preparation method: 0.01 mg of P2VP (poly 2-vinyl pyridine) and a certain amount of FeCl 3 6H2 O(molar ratio Fe 3+ / pyridine = 60) was dissolved in 10 mL of CH 2 Cl 2 The mixed solution obtained by stirring for 2 hours until uniform was used as the dispersed phase; a PVA aqueous solution with a mass fraction of 0.4% was used as the continuous phase; and the continuous phase and the dispersed phase were respectively injected into different channels of the T-shaped channel of the microfluidic chip (made of glass), and the flow rate of the dispersed phase was 50 μL min -1 The flow rate of the continuous phase was 6 mL min -1 The dispersed phase is sheared into magnetic microdroplets with a size range of 80 μm by the continuous phase in the microfluidic chip. After filtering out the smaller droplets through a filter membrane with a pore size of 0.45 μm, the resulting product is collected and placed at room temperature to wait for the solvent to evaporate and solidify. After solidification is completed, unnecessary impurities or contamination are removed through dialysis purification, and the prepared Fe 3+ The concentration of magnetic nanoparticles (Fe 3+ 0.06 -P2VP) and stored at 4°C.
[0065] The preparation method of the microfluidic chip in the following example is to pull the orifice of the glass tube to 5-30 μm by using a needle puller P-1000 (Sutter Instrument Co., Ltd., USA), and then coaxially nest the tapered end of the inner capillary into an outer square capillary with an inner diameter of 1.05 mm (Vitro Com, Inc.), and assemble them on a glass sheet in sequence. The dispersed phase flows through the capillary, and the continuous phase flows through the gap between the inner capillary and the outer capillary.
[0066] Example 1
[0067] (1) 0.01 mg PEO-b-P2VP (polyethylene oxide-b-poly 2-vinyl pyridine) was mixed with a certain amount of FeCl 3 6H 2 O(molar ratio Fe 3+ / pyridine = 20) was dissolved in 10 mL of DMF and CH 2 Cl 2 In a mixed solution (DMF and CH 2 Cl 2 The volume ratio of the dispersed phase was 1:10), and after stirring for 2 h until uniform, NaOH solid was added (the concentration of NaOH in the dispersed phase was 4 μM), and stirring was continued overnight until the system was balanced. The obtained mixed solution was used as the dispersed phase;
[0068] (2) preparing a 0.4% by mass PVA (polyvinyl alcohol) aqueous solution as the continuous phase;
[0069] (3) The continuous phase and dispersed phase were injected into different channels of the T-shaped channel of the microfluidic chip (made of glass) at a flow rate of 50 μL min. -1 The flow rate of the continuous phase was 6 mL min -1 The dispersed phase is sheared into magnetic microdroplets with a size range of 80 μm by the continuous phase in the microfluidic chip. After filtering out the droplets with smaller sizes through a filter membrane with a pore size of 0.45 μm, the resulting product is collected and placed at room temperature to wait for the solvent to evaporate and solidify;
[0070] After solidification is completed, unnecessary impurities or contamination are removed by dialysis purification, and the prepared Fe 3+ The concentration of magnetic nanoparticles (Fe 3+ 0.02 -OCPCs) and stored at 4°C.
[0071] Fe 3+ 0.02 -SEM images of OCPCs are shown in Figure 1 , TEM image see Figure 2 .Depend on Figure 1 and Figure 2 It can be seen that Fe 3+ 0.02 -OCPCs magnetic nanoparticles have a distinct core-onion ring-shaped multilayer shell-porous crown structure, with hexagonal and tightly arranged holes in the shell layer ranging from 20 to 100 nm in size. In this unique structure, the onion ring-shaped multilayer shell comes from the regulation of the self-assembly process of block copolymers in the preparation strategy of dual kinetic path control, and the porous crown comes from the regulation of the droplet self-emulsification process in the preparation strategy of dual kinetic path control. 3+ 0.02 -Schematic diagram of the three-dimensional model of OCPCs Figure 3 .
[0072] Example 2
[0073] (1) 0.01 mg of PEO-b-P2VP was mixed with a certain amount of FeCl 3 6H 2 O(molar ratio Fe 3+ / pyridine = 40) was dissolved in 10 mL of DMF and CH 2 Cl 2 In a mixed solution (DMF and CH 2 Cl 2 The volume ratio of the dispersed phase was 1:10), and after stirring for 2 h until uniform, NaOH solid was added (the concentration of NaOH in the dispersed phase was 4 μM), and stirring was continued overnight until the system was balanced. The obtained mixed solution was used as the dispersed phase;
[0074] (2) preparing a 0.4% PVA aqueous solution as the continuous phase;
[0075] (3) The continuous phase and dispersed phase were injected into different channels of the T-shaped channel of the microfluidic chip (made of glass) at a flow rate of 50 μL min. -1 The flow rate of the continuous phase was 6 mL min -1 The dispersed phase is sheared into magnetic microdroplets with a size range of 80 μm by the continuous phase in the microfluidic chip. After filtering out the droplets with smaller sizes through a filter membrane with a pore size of 0.45 μm, the resulting product is collected and placed at room temperature to wait for the solvent to evaporate and solidify;
[0076] After solidification is completed, unnecessary impurities or contamination are removed by dialysis purification, and the prepared Fe 3+ The concentration of magnetic nanoparticles (Fe 3+ 0.04 -OCPCs) and stored at 4°C.
[0077] Fe 3+ 0.04 -SEM images of OCPCs are shown in Figure 4 , TEM image see Figure 5 .Depend on Figure 4 and Figure 5 It can be seen that Fe 3+ 0.04 -OCPCs magnetic nanoparticles have a distinct core-onion ring-shaped multilayer shell-porous crown structure, the proportion of macropores in the pores in the shell layer is significantly increased, the average pore size is increased, the porosity is increased, the arrangement of pores becomes more compact, and the Fe prepared in Example 1 is lost. 3+ 0.02 -OCPCs. This structural difference comes from the increase of Fe 3+ The concentration of FeO2 can precisely control the dual dynamic paths inside the droplet, thereby obtaining nano-metamaterials with more complex structures. 3+ 0.04 -Schematic diagram of the three-dimensional model of OCPCs Figure 6 .
[0078] Example 3
[0079] (1) 0.01 mg of PEO-b-P2VP was mixed with a certain amount of FeCl 3 6H 2 O(molar ratio Fe 3+ / pyridine = 60) was dissolved in 10 mL of DMF and CH 2 Cl 2 In a mixed solution (DMF and CH 2Cl 2 The volume ratio of the dispersed phase was 1:10), and after stirring for 2 h until uniform, NaOH solid was added (the concentration of NaOH in the dispersed phase was 4 μM), and stirring was continued overnight until the system was balanced. The obtained mixed solution was used as the dispersed phase;
[0080] (2) preparing a 0.4% PVA aqueous solution as the continuous phase;
[0081] (3) The continuous phase and the dispersed phase were injected into different channels of the T-shaped channel of the microfluidic chip (made of glass) respectively. The flow rate of the dispersed phase was 50 μL min -1 The flow rate of the continuous phase was 6 mL min -1 The dispersed phase is sheared into magnetic microdroplets with a size range of 80 μm by the continuous phase in the microfluidic chip. After filtering out the droplets with smaller sizes through a filter membrane with a pore size of 0.45 μm, the resulting product is collected and placed at room temperature to wait for the solvent to evaporate and solidify;
[0082] After solidification is completed, unnecessary impurities or contamination are removed by dialysis purification, and the prepared Fe 3+ The concentration of magnetic nanoparticles (Fe 3+ 0.06 -OCPCs) and stored at 4°C.
[0083] Fe 3+ 0.06 -SEM images of OCPCs are shown in Figure 7 , TEM image see Figure 8 .Depend on Figure 7 and Figure 8 It can be seen that Fe 3+ 0.06 -OCPC magnetic nanoparticles have a distinct core-onion ring-shaped multilayer shell-porous crown structure, and the porosity in the shell layer is comparable to that of the Fe prepared in Example 2. 3+ 0.04 -OCPCs are further improved, the arrangement of pores is more irregular, and the size range of pores shows an irregular distribution of micropores, mesopores and macropores. 3+ 0.06 -OCPCs have a cap thickness of about 50 nm and the internal pore size distribution BET data are shown in Fig. 9 TEM pseudo-color image is shown in Fig.10 ,Depend on Fig.10 It can be seen that Fe 3+ 0.06 The thickness of the onion ring-shaped shells in the OCPCs magnetic nanoparticles are: PEO layer (blue) 13nm, Fe 3+ / P2VP layer (orange) 15nm. Compared with Example 1 and Example 2, the Fe3+ 0.06 -OCPCs have the most complex structure, which comes from the change of Fe 3+ Concentration precisely controls the dual mechanical processes in droplets. 3+ 0.06 -Schematic diagram of the three-dimensional model of OCPCs Fig.11 .
[0084] Example 4
[0085] In this example, Fe prepared in Example 1 is selected 3+ 0.02 -OCPCs and Fe prepared in Example 3 3+ 0.06 -OCPCs, and Fe 3+ 0.06 -P2VP for T 1 Imaging contrast agent. T of the above embodiment 1 Weighted imaging Fig.12 As shown, the longitudinal relaxation rate r 1 The relationship between the contrast agent concentration and Fig.13 The specific implementation method is to prepare Fe 3+ Concentration of 0-0.1 mM Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 -P2VP dispersion, through the mouse bodyT of 1.5T small animal nuclear magnetic imaging instrument 1 In vitro T was measured with Fast Spin Echo 2D sequence 1 Weighted imaging ( Fig.12 ) ; The longitudinal relaxation rate r was measured by CPMG sequence and IR sequence of 0.5T magnetic resonance imaging analyzer 1 Relationship with contrast agent concentration ( Fig.13 ). These data indicate that compared with the simple structure of Fe 3+ 0.06 -P2VP, Fe with complex hierarchical structure 3+ 0.02 -OCPCs and Fe 3+ 0.06 -OCPCs have better T 1 Weighted in vitro imaging effect. Considering the safety of contrast agents, we investigated Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe3+ 0.06 - Cytotoxicity of P2VP ( Fig.14 The specific implementation method is to inoculate HeLa cells in good cell state into a 96-well plate and incubate them in 1640 culture medium overnight (about 5×10 cells per well). 4 After the cells have attached to the wall and grown, the original culture medium is replaced with one containing Fe 3+ Concentration of 0-20 mM Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs and Fe 3+ 0.06 -P2VP 100uL of fresh culture medium. Incubate in the incubator for 30min. Add 10uL of cck-8 to each well of the 96-well plate, continue to culture in the incubator for 2.5h, measure the absorbance at 450nm wavelength in an ELISA instrument to detect cell survival rate and growth status. The data showed that the cell inventory rate was basically maintained between 80% and 90%, indicating that the prepared Fe 3+ 0.06 -P2VP, Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs have good biosafety.
[0086] BALB / c nude mice aged 4 to 6 weeks were selected for subcutaneous tumor imaging. Each mouse was injected with 5×10 6 After about one week of culture, the tumor diameter reached 1-4 mm. At this time, the mice were injected with contrast agent (injection volume 200 μL, containing Fe 3+ The concentration of Fe was 20 μM 3+ 0.06 -P2VP, Fe 3+ 0.02 -OCPCs, Fe 3+ 0.06 -OCPCs), and then MRI was performed using the Bruker BioSpec3T MRI animal in vivo imager. MRI T 40 min after injection 1 Imaging data such as Fig.15 :Compared to the simple structure of Fe 3+ 0.06 -P2VP, a nano-metamaterial Fe with complex hierarchical structure 3+ 0.02 -OCPCs and Fe 3+ 0.06 -OCPCs have a more obvious signal change; compared with Fe3+ 0.02 -OCPCs, by regulating Fe 3+ concentration to obtain Fe with a higher porosity shell 3+ 0.06 The signal changes of -OCPCs are more obvious. The above data show that the nano-metamaterials prepared by the present invention have biological imaging performance that exceeds that of materials with simple structures, and this performance can be reasonably controlled by regulating the key parameters of the dual kinetic pathways.
[0087] Example 5
[0088] In this example, Fe prepared in Example 3 is selected 3+ 0.06 -OCPCs, Fe 3+ 0.06 -P2VP and diethylenetriaminepentaacetic acid gadolinium Gd (DTPA) are T 1 Imaging contrast agent. Zebrafish embryos at 98 hours of development were selected for high magnetic field MR imaging. 3 + 0.06 -OCPCs, Fe 3+ 0.06 -P2VP and Gd(DTPA) were formulated into each Fe 3+ or Gd 3+ The concentration of 0.1M was injected into zebrafish embryos evolving from a single cell to a four-cell state. After 98 hours of embryonic development, the embryos were observed using a Bruker BioSpec 7TMRI in vivo animal imaging system. Fig.16 , compared to the commercial T 1 Imaging contrast agent Gd(DTPA) and Fe with simple structure 3+ 0.06 -P2VP, a nano-metamaterial Fe with a more complex hierarchical structure prepared by dual kinetic pathway control 3+ 0.06 -OCPCs signal changes are more obvious, T 1 The imaging effect is better.
Claims
1. A method for preparing a nano-metamaterial, comprising the following steps: (1) mixing a block copolymer capable of coordinating with metal ions, metal ions and a solvent, and then adding a base to prepare a dispersed phase solution; In step (1), the method for preparing the dispersed phase solution is to dissolve the block copolymer capable of coordinating with the metal ions and the metal ions in the solvent, stir for at least 2 hours, then add the base and continue stirring until the system is in equilibrium, thereby obtaining the dispersed phase solution; The block copolymer is polyethylene oxide-b-poly 2-vinyl pyridine; The metal ion is Fe 3+ ; The solvent is at least one of CH2Cl2 and N,N-dimethylformamide; The alkali is sodium hydroxide and / or potassium hydroxide; In the dispersed phase solution, the concentration of the block copolymer is 0.001-0.1 mg / mL; the concentration of the base is 3-5 μM; The molar ratio of the metal ion to the pyridine group in the block copolymer is 20 to 60:1; (2) Prepare a continuous phase solution by combining a surfactant and a highly polar liquid; The surfactant is polyvinyl alcohol; The highly polar solvent is water; The mass percentage concentration of the surfactant in the continuous phase solution is 0.2-0.6%; (3) preparing a primary emulsion droplet using the dispersed phase solution and the continuous phase solution; In step (3), the method for preparing the primary emulsion droplets is microfluidics; (4) The primary emulsion droplets are passed through a filtration membrane to prepare secondary emulsion droplets, which are then solidified to obtain the nano-metamaterial.
2. The preparation method according to claim 1, characterized in that: In step (4), the filter membrane used to prepare the secondary emulsion droplets is a filter membrane with a pore size of 0.10-0.45 μm; The curing is the natural volatilization of the solvent under room temperature.
3. The preparation method according to claim 2, characterized in that: In the microfluidic method, the microfluidic device used is a microfluidic chip with a channel shape of T-type, L-type, Y-type or cross-type; The material of the microfluidic chip is polydimethylsiloxane, quartz, glass or stainless steel; The flow rate of the dispersed phase is 1-1000 μL min -1 The flow rate of the continuous phase is 1-1000 mL min -1 .
4. The preparation method according to claim 3, characterized in that: The flow rate of the dispersed phase was 50 μL min -1 The flow rate of the continuous phase is 5-6 mL min -1 .
5. The nano-metamaterial prepared by the preparation method according to any one of claims 1 to 4.
6. The nano-metamaterial according to claim 5 is used in the preparation of magnetic resonance imaging T 1. Application of contrast agents.
7. The nano-metamaterial according to claim 5 is used in the preparation of 7T ultra-high field magnetic imaging T 1. Application of contrast agents.
Citation Information
Patent Citations
Magnetic microgel for coating cells as well as preparation method and application thereof
CN113730610A
Quantum dot film having porous structure and manufacturing method for the same
US20190379001A1
